Unraveling potential EGFR kinase inhibitors: Computational screening, molecular dynamics insights, and MMPBSA analysis for targeted cancer therapy development
PLOS One · 2025
DOI: 10.1371/journal.pone.0321500 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Muhammad Naseem Khan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, COMSATS University Islamabad, Abbottabad Campus, Abbottabad, Pakistan. Hauptthemen laut MEDLINE: ErbB Receptors, Protein Kinase Inhibitors, Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Research Supporting Project of King Saud University, Riyadh, Saudi Arabia.
Abstract (Originalsprache)
EGFR is critical for tumor angiogenesis and cancer progression, but existing treatments like erlotinib face limitations such as acquired resistance and side effects. To address these issues, this study employs structure-based drug design techniques including virtual screening, molecular docking, and molecular dynamics simulations to identify new small molecule inhibitors targeting the EGFR kinase domain. From an initial selection of 633,000 compounds from diverse databases, top candidates were identified based on their binding affinity and stability. The virtual screening and docking analyses revealed compounds with higher binding scores than erlotinib. Molecular dynamics simulations and Anisotropic Network Model (ANM) analysis uniquely report that EGFR undergoes significant conformational shifts: inward flap movements in the bound state stabilize a closed conformation, while outward movements in the free state result in a more open conformation. Among the identified inhibitors, compounds such as JFD00243, NPA015124, and others exhibited strong binding affinities and stable interactions with both active and inactive forms of EGFR. Notably, JFD00243 was effective in targeting EGFR in both active and inactive conformations. These findings suggest that the identified inhibitors could potentially overcome current treatment limitations and improve targeted cancer therapies by effectively inhibiting EGFR-mediated tumor angiogenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, COMSATS University Islamabad, Abbottabad Campus, Abbottabad, Pakistan.
- Beijing National Laboratory for Molecular Sciences, State Key Laboratory of Molecular Reaction dynamics, Institute of Chemistry, Chinese Academy of Sciences, Beijing, China.
- Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
- Department of Biochemistry, College of Science, King Saud University, Riyadh, Saudi Arabia.
- Department of Chemistry, Pennsylvania State University, University Park, Pennsylvania, United States of America.
ORCID-Profile: Muhammad Naseem Khan, Sara Khan
Förderung
- the Research Supporting Project of King Saud University, Riyadh, Saudi Arabia
Zitieren
APA
Khan, M. N., Farooq, U., Khushal, A., Wani, T. A., Zargar, S., & Khan, S. (2025). Unraveling potential EGFR kinase inhibitors: Computational screening, molecular dynamics insights, and MMPBSA analysis for targeted cancer therapy development. PLOS One. https://doi.org/10.1371/journal.pone.0321500
Vancouver
Khan MN, Farooq U, Khushal A, Wani TA, Zargar S, Khan S. Unraveling potential EGFR kinase inhibitors: Computational screening, molecular dynamics insights, and MMPBSA analysis for targeted cancer therapy development. PLOS One. 2025. doi:10.1371/journal.pone.0321500
BibTeX
@article{Khan2025,
author = {Khan, Muhammad Naseem and Farooq, Umar and Khushal, Aneela and Wani, Tanveer A and Zargar, Seema and Khan, Sara},
title = {Unraveling potential EGFR kinase inhibitors: Computational screening, molecular dynamics insights, and MMPBSA analysis for targeted cancer therapy development},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0321500}
}
EUVIMED